Polyphosphazene delivery system for inorganic nanocrystals
Nanoclusters comprising inorganic nanocrystals and a biodegradable polymer are disclosed. The inorganic nanocrystals have a mean particle size of 1 to 500 nm. The inorganic nanocrystals are contained within a core of the nanoclusters, on the surface of the nanoclusters, contained within a core of the nanoclusters, dispersed throughout the nanoclusters, or a combination thereof. The biodegradable polymer allows the inorganic nanocrystals to be excreted renally over a period of time. The nanoclusters can be used for medical imaging or other biomedical applications.
1. A nanocluster comprising:
a plurality of hydrophilic inorganic nanocrystals, each comprising:
a gold nanocrystal having a mean size of about 5 nm or less; and
a first hydrophilic ligand coating selected from the group consisting of: 11-mercaptoundecanoic acid, glutathione and citrate;
a hydrophilic biodegradable polymer encapsulating the plurality of hydrophilic inorganic nanocrystals, wherein:
the hydrophilic biodegradable polymer is adapted to degrade over time by hydrolysis; and
the hydrophilic biodegradable polymer is polyphosphazene; and
a second ligand coating the surface of the hydrophilic biodegradable polymer, wherein the second ligand is PEG;
wherein the nanocluster has a mean size in the range of from about 10 nm to about 300 nm.
2. The nanocluster according to claim 1 , wherein the polyphosphazene is selected from the group consisting of poly(bis(4-carboxyphenoxy)phosphazene) (PCPP) and poly(carboxylatophenoxy)(glycinato) polyphosphazenes (PCGPPs).
3. The nanocluster according to claim 1 , wherein the polymer is crosslinked.
4. The nanocluster according to claim 3 , wherein the polymer is crosslinked with spermine.
5. The nanocluster according to claim 1 , wherein the plurality of hydrophilic inorganic nanocrystals are positioned on a surface of the polymer.
6. The nanocluster according to claim 1 , further comprising a drug contained on the surface of the nanocluster, contained within the core of the nanocluster, dispersed throughout the nanocluster, or a combination thereof.
7. A method comprising:
administering to a patient a plurality of nanoclusters according to claim 1 ; and
imaging the patient with x-ray imaging, computed tomography (CT), magnetic resonance imaging (MRI), photoacoustic imaging, fluorescence, or fluoroscopy.
8. A method for enhancing the effect of radiation therapy, comprising:
administering to a patient a plurality of nanoclusters according to claim 1 ; and
treating the patient with radiation at a targeted site, wherein the plurality of nanoclusters increase the amount of radiation absorbed at the targeted site.
9. A method for ablating tissue, comprising:
administering to a patient a plurality of nanoclusters according to claim 1 ; and
treating the patient with electromagnetic radiation at a targeted site, wherein the plurality of nanoclusters absorb the electromagnetic radiation and convert the electromagnetic radiation to heat to ablate the tissue at the targeted site.